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The effect of berberine supplementation on obesity indices: A dose– response meta-analysis 





Background and purpose: Clinical studies investigating the effects of berberine supplementation 
on anthropometric indices in humans have generated inconsistent results. Thus, the objective of 
this systematic review and meta-analysis was to clarify the effects of berberine supplementation 
on obesity indices in human subjects. 
 
Methods: Several online medical databases were systematically searched up to February 2019. 
All clinical trials exploring the effects of berberine supplementation on indices of obesity were 
included. The combined weighted mean difference (WMD) of eligible studies was assessed using 
a random-effects model. We evaluated publication bias by using the Egger’s test. 
 
Results: Overall, 10 studies were included. The combined outcomes suggested a significant 
 
influence of berberine administration on body mass index (BMI) (WMD: -0.29 kg/m
2
, 95% CI: - 
0.51 to -0.08, p = 0.006) and waist circumference (WC) (WMD: -2.75 cm, 95% CI: -4.88 to -0.62, 
p = 0.01). However, berberine supplementation yielded no significant decline in body weight (BW) 
(WMD: -0.11 kg, 95% CI: -0.99 to 0.76, p = 0.79). Following the dose-response evaluation, 
berberine intake was found to significantly reduce BMI (r = -0.02) and WC (r = -0.72) based on 
treatment duration. 
 
Conclusion: The results of the current study support the use of berberine supplementation for the 
improvement of obesity indices. 
 











Obesity can be attributed to an imbalance between energy expenditure and energy intake and has 
become a major public health problem, mainly due to its association with type 2 diabetes mellitus, 
non-alcoholic fatty liver disease, hypertension, insulin resistance, cardiovascular disorders and a 
myriad of other cardiometabolic diseases [1-2]. Although exogenous factors, such as an excessive 
caloric intake and a sedentary lifestyle, play the most important role in the current obesity 
epidemic, endogenous factors, e.g. specific gene variants may predispose certain individuals to 
become obese [3]. Worldwide, more than one-third of adults are affected by obesity [4]. Although 
traditional pharmacotherapy remains a key element in the treatment of obesity and obesity-related 
comorbidities, many researchers have also investigated the effects of natural products in the 
management of obesity. Due to their anti-obesity properties, these substances have been employed 
either as adjuncts to conventional drugs or in monotherapy [5-6]. 
 
One such example is the plant alkaloid berberine, which is considered an inexpensive and safe oral 
supplement commonly used as an over-the-counter (OTC) drug due to its myriad of effects on 
human health. Berberine is known to increase insulin sensitivity, lower blood glucose, reduce the 
risk of metabolic syndrome, improve lipid metabolism and stimulate weight loss [7]. Previous 
reports have highlighted that berberine increases the mRNA expression of adiponectin, inhibits the 
differentiation of adipocytes, regulates glucose and lipid metabolism, and decreases the secretion 
of leptin and resistin [8]. 
 
Recently, a randomized controlled trial reported no change in body mass index (BMI), waist 
circumference (WC) or body weight (BW) following berberine supplementation. However, the authors 
reported other beneficial metabolic effects of berberine, such as a reduction in hemoglobin A1C 
(HbA1c) and triglyceride levels [9]. Contrastingly, the administration of 500 mg of berberine 
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either twice [10] or three times daily [11] for a period of three months resulted in a decrease in 
BW, BMI and WC [10, 11]. The duration of the intervention seems to play a role in the effects of 
this natural product, since a shorter administration of berberine supplements in some clinical trials 
as opposed to others might explain why the authors did not record a significant decrease in BMI 
even if the dose of berberine was the same in all of these studies [10, 12-13]. 
 
Thus, due to the conflicting results of these previous interventions, the aim of our systematic 
review and meta-analysis was to evaluate the impact of berberine supplementation on obesity 




The current study has been conducted in accordance with the Preferred Reporting Items of 
Systematic Reviews and Meta-Analyses (PRISMA) protocol [14]. 
 
2.1. Search Strategy 
 
In order to identify eligible studies, we searched several online databases (the Cochrane Library, 
Scopus, PubMed-MEDLINE and Google Scholar) from their establishment up to February 2019. 
The following medical subject headings (MeSH) and non-MeSH keywords were employed: 
"Berberine" AND "Cross-Over Studies" OR "Clinical Trials" OR "Double-Blind Method" OR 
"Random Allocation" OR "RCT" OR "Single-Blind Method" OR "Intervention Studies" OR 
"controlled trial" OR "randomised" OR "randomized" OR "random" OR "intervention" OR 
"randomly" OR "assignment" OR "placebo". Ultimately, we manually searched the references of 
the eligible studies to identify any missing studies relevant to our objective. 
 
2.2. Eligibility criteria 
 
The eligibility criteria for the search process and meta-analysis were defined via the PICO method: 
definition of the Population (P), Intervention (I), Comparison (C) and Outcomes (O). Firstly, the 
population consisted of adult subjects suffering from various health conditions. Secondly, we 
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included only randomized controlled trials in our evaluation. Thirdly, the intervention consisted in 
berberine supplementation to the recruited subjects. Fourthly, the included studies investigated the 
impact of berberine supplementation in an intervention group versus a control group. Fifthly, 
sufficient information on BMI, WC and BW was reported for both the intervention group and the 
control group. Finally, the studies were published in English. We excluded clinical trials without 
a suitable control group. In addition, we excluded the publications that did not provide outcome 
measures at the beginning of the study and at the end of the intervention. 
 
2.3. Data extraction 
 
Two independent investigators (J.R. and H.K.-V.) scanned and extracted the relevant information. 
Where necessary, a senior investigator (S.J.M.R.) helped to achieve consensus. If the information 
found in the articles was incomplete, we communicated with the lead authors of the papers for 
clarifications. The following information was extracted from each included trial: the first author 
of the study, the design of the study, the health status of the participants involved, the year of 
publication, the study location (country), the sample size of the study groups and of the control 
groups, the mean age of the participants, the gender of the participants, the dose of berberine 
administered, the duration of the intervention and the findings (means and standard deviation of 
the BMI, WC and BW at the beginning and the end of the study and/or changes between the 
beginning and the end of the supplementation with berberine). If a trial reported duplicate data, we 
considered the reports with complete follow-up and results. 
 
2.4. Quality assessment of publications 
 
The quality of the eligible trials was evaluated using the Cochrane Collaboration’s tool for 
assessing the risk of bias which takes into consideration the following items: allocation 
concealment, random sequence generation, blinding of outcome assessment, blinding of 
participants and personnel, selective reporting, incomplete outcome data and other probable 
sources of biases. In order to evaluate the quality of the selected trials, each study was allotted a 
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label (yes, no or unclear) and graded as low-risk, high-risk or unknown risk of bias, respectively 
[15]. 
 
2.5. Quantitative data synthesis 
 
We performed all statistical analyses using the Stata program (Stata Corp. College Station, Texas, 
USA). The combined effect size was computed based on the mean difference and the standard 
deviation (SD) of the outcome measures. The random-effects model (using the DerSimonian-Laird 
method) was applied in order to evaluate effect sizes and the results were reported based on the 
weighted mean difference (WMD) and 95% confidence intervals (CI). If the SD of the mean change 
was not described in the publications, we calculated it using the next formula: SD alteration= square 
root [(SD baseline
2
 + SD end
2
) - (2 × R × SD baseline × SD end)] [16]. Heterogeneity was evaluated 
using Cochran's Q-test (significance set at less than 0.05) and the I 
2
 statistic were applied for 
calculating the percentage of heterogeneity among studies. We carried out predefined stratified 
analyses based on sex (women and men), berberine dosage (≤1 g and ˃1 g) and intervention duration 
(≤12 weeks and ˃12 weeks). Subgroup analyses for berberine dosage and intervention duration were 
based on the median cut-off of the qualified studies and were performed using a fixed-effects model. 
Publication bias was evaluated via the Egger’s test and visual appraisal of the funnel plots [17]. The 
“trim and fill” approach was applied to revise any detected publication bias 
 
[18]. Sensitivity analyses were performed using the metaninf test to evaluate the consistency
of the outcomes. We evaluated the non-linear possible impact of berberine dosage (g/day) and 




3.1. Study selection and systematic review 
 
We retrieved 1410 publications from PubMed-MEDLINE, Scopus, the Cochrane Library and 
Google Scholar out of which 324 were duplicate publications and therefore excluded. After 
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reviewing the title and abstract of the remaining papers, 979 manuscripts were subsequently excluded. 
In the next step, we screened the remaining 107 papers by evaluating the full-text and we excluded 98 
papers due to the following reasons: inclusion of a co-intervention, review articles, duplicate data and 
no data of interest (Supplementary Figure 1). Finally, 9 articles were included in our study. Nine 
studies reported BMI [7, 10-13, 20-23], five reported BW [10, 13, 20-22] and seven reported WC [7, 
11, 20, 22, 23]. Pérez-Rubio et al. reported WC separately for men and women [11]. The duration of 
the interventions varied between 4 to 52 weeks. The age of the individuals ranged from 26 to 65 years. 
The eligible trials were published between 2010 and 2018 [7, 10-13, 20-23]. One study was conducted 
on males [11] and five studies were conducted on females [7, 11, 13, 20, 22]. All studies were 
controlled trials and one had a cross-over design [10]. The dose of berberine supplementation ranged 
from 1000 to 3000 milligrams/day. The studies were conducted in various countries: five in China [7, 
13, 20, 22, 23], two in Iran [12, 21], one in Italy [10] and one article included two studies conducted 
in Mexico [11] (Table 1). 
 
3.2. Quality assessment 
 
The methodological quality and risk of bias of the eligible trials are reported in Supplementary 
Table 1. Most trials had good quality based on the Cochrane collaboration's tool criteria. For some 
studies, the risk of bias originated from the “incomplete outcome data” item [7, 10, 12, 22, 23] and 
from the “blinding of participants” item [20]. 
 
 
3.3. Meta-analysis results 
 
Five arms, with a total of 378 individuals (control=187 and case=191), described BW as a result 
measure. The pooled outcomes from the random-effects model specified that berberine 
intervention did not alter BW significantly (WMD: -0.11 kg, 95% CI: -0.99 to 0.76, p = 0.79), with 
no significant heterogeneity across the studies (I
2




Nine studies, with a total of 983 individuals (control=499 and case=484), described BMI as a result 
measure. The combined outcomes from the random-effects model demonstrated that berberine 
supplementation resulted in a significant decrease in BMI (WMD: -0.29 kg/m
2
, 95% CI: -0.51 to 
-0.08, p = 0.006), with no significant heterogeneity across the studies (I
2
 = 0.0%, p = 0.85) (Figure 
2). 
 
Moreover, seven studies, including a total of 841 (case=423 and control=418) individuals, 
presented data for WC as an outcome evaluation. The combined results from the random-effects 
model reported that berberine supplementation resulted in a significant reduction in WC (WMD: 
-1.78 cm, 95% CI: -3.17 to -0.39, p=0.01), with a significant heterogeneity across the studies (I
2
= 
73.5%, p= 0.001) (Figure 3). We stratified the studies based on the duration of the trial (weeks), 
the dose of berberine administered (mg/day) and the sex of the participants (female, male or both 
sexes included in the study) to investigate the possible sources of heterogeneity. We found 
heterogeneous values for the dosage of berberine (g/day) (˃1 g: I
2
=3.4%, p=0.39) and the sex of 
the participants (females: I
2
=34.8%, p=0.20). Moreover, the subgroup analyses showed that 
berberine supplementation yielded greater reductions in WC in females (WMD: -2.45 cm, 95% 
CI: -3.48 to -1.43, p < 0.001) and at a dosage ˃1 g (WMD: -2.37 cm, 95% CI: -3.29 to -1.44, p < 
0.001) (Supplementary Table 2). The sensitivity analysis revealed that no individual study had a 
significant influence on the results of this meta-analysis (Supplementary Figure 2). 
 
3.4. Non-linear dose-responses between the duration and the dose of berberine intervention 
 
and the results 
 
Following the dose-response assessment, berberine intervention significantly reduced BMI (r= - 
0.02, P-nonlinearity= 0.004) depending on the duration of the intervention, but in a non-linear 
fashion (Figure 4). 
 






The evaluation of the publication bias by visual examination of the funnel plots revealed possible 
publication bias in the meta-analysis of the effect of berberine supplementation on WC. In 
addition, we did not detect any publication bias for the effect of berberine supplementation on BW 




The management of obesity primarily consists of lifestyle changes and pharmacological interventions, 
often requiring multiple drugs to achieve success [24]. Due to its anti-obesity and blood glucose-
lowering properties, berberine, a plant alkaloid frequently employed in traditional Chinese medicine, 
has been used in humans to prevent the development of metabolic diseases [25]. Even if several studies 
conducted both in animals and humans have highlighted positive outcomes following supplementation 
with berberine, its overall efficacy remains unclear. Therefore, in the present study, we sought to 
evaluate the effect of berberine supplementation on indices of obesity. Thus, to accomplish this aim, 
the current systematic review and meta-analysis included available RCTs which examined the effects 
of berberine supplementation on BMI, WC and BW in adults. Our results indicate that berberine 
supplementation is associated with a significant reduction in BMI and WC, but not in BW. Following 
the subgroup analysis, we report that berberine supplementation reduced WC, particularly in females, 
in subjects with a baseline BMI >30 kg/m
2
, when the duration of the intervention exceeded 12 weeks 
and when the dose exceeded 1 g/day. 
 
 
Moreover, several trials have reported that berberine can also increase the energy expenditure and the 
consumption of lipid metabolites as primary energy sources in obese animals, in addition to lowering 
BW and the white adipose tissue to body weight ratio [26, 27]. Our study also reported that the 
administration of berberine resulted in a significant reduction of the BMI (-0.29 kg/m
2
, 95% CI: -0.51 
to -0.08, p = 0.006), with no significant heterogeneity among the evaluated studies. On the same hand, 
subjects who were prescribed berberine also benefited from a significant 
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reduction in WC (-2.75 cm, 95% CI: -4.88 to -0.62, p = 0.01), with significant heterogeneity among 
the evaluated studies (I
2
 = 90.6 %, p = 0.001). 
 
Our results indicated significant changes in BMI and WC following berberine supplementation. 
However, the independent evaluation of the effect of berberine on BW, based on the combined 
results from the random-effects model, revealed no significant changes in BW after 
supplementation with berberine. This finding is paradoxical, since BW is used in the calculation 
of the BMI, and might arise from a low statistical power of the studies included in the analysis, 
some of which having samples as low as 12 individuals/group. On the same hand, reports which 
included small samples might overestimate the effects of berberine supplementation as compared 
to studies including a higher number of recruited participants [28]. In addition, our meta-analysis 
included only five studies that evaluated changes in BW following berberine supplementation, 
whereas seven of the included studies reported information regarding the effect of berberine on 
BMI and WC. Clearly, this contradiction may impede the reliability and clinical applicability of 
our results. Although we did not report a significant decrease in BW, overall the anthropometric 
indices improved following berberine supplementation (e.g. WC, which is a morphological 
characteristic of weight loss, decreased). 
Interestingly, studies conducted on preclinical models revealed that animals which were given 
berberine did not lose weight, but were protected against gaining weight following the intervention. 
Nevertheless, positive metabolic effects of berberine are frequently reported in the literature [29]. The 
crosstalk between obesity and insulin resistance, which contributes to the development of the metabolic 
syndrome, might be explained by the unfavorable changes in the secretion of adipokines in obese 
subjects, regarded as an early sign of an impaired function of the adipose tissue [8]. Preliminary 
evidence on the mechanistic effects of berberine on serum adipokines suggests that berberine 
supplementation improves insulin sensitivity. Yang et al. have reported that the administration of 
berberine inhibits the differentiation of preadipocytes in human 
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subjects and that patients diagnosed with metabolic syndrome who were prescribed berberine 
benefited from a reduction in BMI, leptin/adiponectin ratio and leptin levels [8]. Unfortunately, 




We highlighted that berberine supplementation yielded a significant reduction in BMI and WC, 
but not BW and that berberine was more effective in participants with a baseline BMI greater than 
30 kg/m
2
, in females, in subjects who were given a dose >1 g/day and in participants who received 
supplements for >12 weeks. However, the exact mechanisms explaining the effects of berberine 
on the metabolism of glucose are still unclear. Studies have reported that berberine 
supplementation increases glucose consumption and/or glucose uptake in adipocytes and 
hepatocytes even in the absence of insulin [30]. Insulin and berberine act employ different 
mechanisms to stimulate glucose uptake, the latter stimulating the activity of the adenosine 
monophosphate-activated protein kinase (AMPK) [31, 32]. Moreover, berberine upregulates the 
insulin receptor at a transcriptional level by stimulating the insulin receptor promoter [22, 33] and 
is responsible for an increase in glucose transporter-4 (GLUT-4) and glucagon-like peptide-1 
(GLP-1) levels. All of the above mechanisms are associated with the anti-obesity effects of 
berberine [34] and may partially explain the reduction in BW and BMI recorded in our study. 
Moreover, the aforementioned mechanisms might explain why berberine supplementation was 
more efficient in participants with a baseline BMI greater than 30 kg/m
2
. In terms of the 
metabolism of lipids, the lipid-lowering effects of berberine are apparently attributed to the 
stabilization of the hepatic low-density lipoprotein receptor (LDL-R) by the extracellular signal-
regulated kinase-dependent pathways and also to the increase of the transcriptional activity of the 
LDL-R promoter [34]. Clearly, the mechanisms employed by berberine require further 
investigation to explain the effects of this natural compound on human health. 
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4.1. Strength and limitations 
 
The primary strength of this study was that this is the first meta-analysis of RCTs to assess the 
impact of berberine supplementation on indices of obesity. The evidence base prior to this meta-
analysis was not uniform and required a quantitative assessment which we have provided. We have 
demonstrated that there is sufficient evidence to conclude that berberine supplementation has a 
positive effect on the BMI and WC of humans. Another strength of the current meta-analysis is 
the assimilation of a heterogeneous sample of participants. We were also able to stratify analyses 
based on the duration of berberine supplementation, the dosage employed and the starting weight 
of the participants. 
 
Notwithstanding, the current study has some limitations. We did not restrict the analyses in terms of 
patients included in the assessed studies. Consequently, this allowed for a larger number of studies and 
participants to be included in our analysis. Furthermore, since this is the first meta-analysis to assess 
the impact of berberine supplementation on obesity indices, it can serve as guidance for further 
investigations in the field. Since the sample sizes of some RCTs included in our analysis were small, 
the results of these studies might be overestimated, as previously reported 
 
[28]. However, this was out of the operational control of our meta-analysis. Another limitation of our 
paper is that the number of eligible studies that could be included in our analysis was low. Thus, there 
is a need for more high-quality RCTs to be conducted to elucidate the effects of berberine 
supplementation on obesity indices. Moreover, we only considered papers that were published in 
English, which conceivably resulted in some potentially relevant studies being omitted, particularly 
given that the published studies included in our analysis originated from China [7, 13, 20, 22, 23], Iran 
[12, 21], Italy [10] and Mexico [11], all of which being countries where English is not the native 
language. An additional consideration is that we only searched the following databases: PubMed-




However, we tried to ameliorate this issue by performing supplementary searches of the reference 





The results of the current study support the use of berberine supplementation for the improvement of 
obesity indices in humans, with sub-group analyses highlighting greater improvements in dosages of 
>1 g/day and when the supplementation exceeded >12 weeks. However, the literature base remains 
equivocal as to whether significant benefits are incurred for weight loss. Thus, even though berberine 
effectively improved some anthropometric indices in the subjects who received the supplements, more 
RCTs are required to understand the clinical relevance of these findings and how these results can be 
translated into the current management of obesity. 
 
Conflict of interest: The authors declare no conflict of interest. 
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Figure 1. Forest plot of randomized controlled trials investigating the effect of berberine 
administration on body weight. WMD= Weighted mean difference; CI= confidence interval 
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Figure 2. Forest plot of randomized controlled trials investigating the effect of berberine 
administration on body mass index (BMI). WMD= Weighted mean difference; CI= 
confidence interval 
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Figure 3. Forest plot of randomized controlled trials investigating the effects of berberine 
supplementation on waist circumference (WC). WMD= Weighted mean difference; CI= 
confidence interval 
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Figure 4. Non-linear dose-responses between berberine supplementation and unstandardized 
mean differences in body weight (kg), body mass index (BMI) (kg/m
2
), and waist 
circumference (WC) (cm). The 95% confidence interval (CI) is depicted in the shaded regions. 
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Figure 5. Funnel plot of the weighted mean difference (WMD) versus the standard error (s.e) of the WMD. 
Table 1. Characteristics of included studies 
 
Author Country Study Sex Age Patient Sample Baseline Dose Outcomes 
 
 (year) design  (year) features size: case/ body weight (mg)  
 
  (duration)    placebo (kg)   
 
          
 
Rashidi Iran Parallel Both 30 - Type 2 22/42 NR 1000 BMI 
 
et al. (2018) 
(4W) 
 65 diabetic     
 
    patients               
 




  ovary     
 
    syndrome               
 
Chang China Parallel Female 51.2 Patients with 41/39 77 1500 BMI, WC, body 
 
et al. (2016) 
(16W) 
  nonalcoholic    weight 
 
    fatty liver               
 
     disease     
 




  ovary     
 
    syndrome               
 
Perez- Mexico Parallel Male 30-40 Metabolic 12/12 NR 1500 BMI, WC 
 
Rubio et (2013) 
(12W) 
  syndrome     
 
al.                   
 
Perez- Mexico Parallel Female 30-40 Metabolic 12/12 NR 1500 WC 
 
Rubio et (2013)    syndrome     
 
al.          
 
Derosa Italy Crossover 
 












Shidfar Iran Parallel 
 














Both 53 Low 68/69 72.3 1000 BMI, WC, body 
  cardiovascular    weight 
  risk     
Female 26 Polycystic 31/28 65.11 1500 BMI, WC, body 
  ovary    weight 
  syndrome     
Both 53.1 Type 2 21/21 75.2 3000 BMI, body weight 
  diabetic     
  patients     
Female 51 Type 2 30/30 68.9 1000 BMI, body weight 
  diabetic     
  patients     
  
W: week, BW: body weight, BMI: body mass index, WC: waist circumference, NR: not reported  
Supplementary Table 1. Cochrane Risk of Bias Assessment    
 Random Allocation Blinding of Incomplete Selective Other 
 sequence concealment participants, outcome outcome sources of 
Study generation  personnel, and data reporting bias 
   outcome    
   assessors    
Rashidi et al. L U L H L U 
Guarino et al. L L L L L U 
Wu et al. L L L H L U 
Chang et al. L U H L L U 
An et al. L L L H L U 
Perez-Rubio et al. L L L L L U 
Perez-Rubio et al. L L L L L U 
Derosa et al. L L L H L U 
Wei et al. L L U H L L 
Shidfar et al. L L L L L U 
Gu et al. L L L L L U 
L, low risk of bias; H, high risk of bias; U, unclear risk of bias. 
Supplementary Data 
 
Supplemental Table 2. Subgroup analysis to assess the effect of berberine supplementation on waist circumference (WC). 
 
Sub-group Number WMD (95% confidences P Value P for heterogeneity I
2
 (%) P for 
 of trials  interval)    between 
       subgroup 
       heterogeneity 
        
Sex       0.018 
Female 4 -2.458 (-3.483 to -1.434) <0.001 0.204 34.8  
Male 1 -1.000 (-4.658 to 2.658) 0.592 - -  
Both 2 -0.133 (-0.735 to 0.469) 0.665 0.068 70.1  
Berberine dosage       0.000 
≤1 g 1 0.000 (-0.618 to 0.618) 1.000 - -  
˃1 g 6 -2.371 (-3.293 to -1.448) <0.001 0.395 3.4  
Intervention duration       0.000 
≤12 weeks 5 -0.643 (-1.189 to -0.098) 0.021 <0.001 80.7  
˃12 weeks 2 -1.446 (-2.969 to 0.078) 0.063 0.329 0.0  
        
 
BMI = Body mass index; WC = Waist circumference; WMD= Weighted mean difference; I
2






























1410 articles identified through   
searching PubMed, Scopus,  
Cochrane Library and Google  










1086 articles screened 
 
 
979 articles excluded based on 
 



























107 full-text articles  
examined for eligibility 
 
98 full-text articles excluded 
 
• No control group  
• Review articles  
• Reported duplicate data  







9 articles with 10 studies were included in the meta-analysis; 
 
body mass index = 9, waist circumference = 7, body weight = 5. 
 
 
Supplementary Figure 1. Flow chart for study identification, screening, eligibility, and 

































































































































Supplementary Figure 2. C: Sensitivity analyses plot (metaninf test) for waist circumference (WC) 
